Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium
- Kliniken Essen-Mitte
- Oslo Metropolitan University
- Centre Leon Berard and University of Lyon
- Coordinating Center for Clinical Trials
- National Cancer Institute of Naples
- University of Milan Bicocca
- Health + Life Gesundheitsmanagement GmbH
- University Hospitals Leuven, Belgium.
- University of Barcelona
- UMC St Radboud Nijmegen
- University of Duisburg-Essen
- National Institute of Oncology
- Centre François Baclesse
- University Hospital Plzeň
- University of Jan Kochanowski
- Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group and Gynecologic Oncology Center
- Universitäts-Klinik Schleswig-Holstein (UKSH) Campus Kiel
- Copenhagen University Hospital Rigshospitalet
- Universita Cattolica del Sacro Cuore Policlinico Gemelli
- Evangelisches Krankenhaus Kalk
- Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCSS)
- Haukeland Universitetssykehus
- Centre Catherine de Sienne
- Boehringer-Ingelheim
194
Link opens in a new tab
Citations
(Scopus)